PROK vs RGEN vs BEAM vs ACAD vs CRSP

For growth investors, ProKidney Corp.

(PROK) is the stronger pick with 1075% revenue growth year-over-year, versus -90. 0% for CRISPR Therapeutics AG (CRSP). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 8x trailing P/E (55. 6x forward), making it the more compelling value choice. Analysts rate ProKidney Corp. (PROK) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACADIA Pharmaceuticals Inc.

(ACAD) is the cheapest at 9. 8x versus Repligen Corporation at 143. 6x. On forward P/E, ACADIA Pharmaceuticals Inc. is actually cheaper at 55. 6x.

Over the past 5 years, ACADIA Pharmaceuticals Inc.

(ACAD) delivered a total return of +6. 6%, compared to -81. 6% for ProKidney Corp. (PROK). Over 10 years, the gap is even starker: RGEN returned +358. 2% versus PROK's -81. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ACADIA Pharmaceuticals Inc.

(ACAD) is the lower-risk stock at 1. 11β versus ProKidney Corp. 's 2. 94β — meaning PROK is approximately 164% more volatile than ACAD relative to the S&P 500. On balance sheet safety, ProKidney Corp. (PROK) carries a lower debt/equity ratio of 1% versus 33% for Repligen Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ProKidney Corp.

(PROK) is pulling ahead at 1075% versus -90. 0% for CRISPR Therapeutics AG (CRSP). On earnings-per-share growth, the picture is similar: Repligen Corporation grew EPS 287. 0% year-over-year, compared to -49. 1% for CRISPR Therapeutics AG. Over a 3-year CAGR, CRSP leads at 100. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus -169. 8% for ProKidney Corp. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -184. 8% for PROK. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ACADIA Pharmaceuticals Inc.

(ACAD) trades at 55. 6x forward P/E versus 61. 7x for Repligen Corporation — 6. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PROK: 151. 1% to $4. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, ACADIA Pharmaceuticals Inc.

(ACAD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 11)). ProKidney Corp. (PROK) carries a higher beta of 2. 94 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACAD: -23. 4%, PROK: -81. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PROK is a small-cap high-growth stock; RGEN is a small-cap high-growth stock; BEAM is a small-cap high-growth stock; ACAD is a small-cap deep-value stock; CRSP is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.